- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 131 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- February 2021
- 420 Pages
United States
From €2282EUR$2,400USD£1,917GBP
- Report
- August 2023
- 103 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
- 74 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
- 114 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Book
- February 2024
- 592 Pages
Imipramine is a tricyclic antidepressant (TCA) used to treat mental disorders such as depression, anxiety, and panic disorder. It is also used to treat bedwetting in children. Imipramine works by increasing the levels of certain neurotransmitters in the brain, which helps to improve mood and reduce anxiety. It is generally well tolerated, but can cause side effects such as dry mouth, constipation, and drowsiness.
Imipramine is one of the oldest and most widely used drugs for treating mental disorders. It is available in both generic and brand-name forms, and is typically prescribed as an initial treatment for depression. It is also used as an adjunct to other medications, such as SSRIs, to treat more severe cases of depression.
The market for mental disorder drugs is highly competitive, with many different companies offering various products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca. Other companies include Bristol-Myers Squibb, Novartis, and Merck. Show Less Read more